• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)

    2/14/22 3:50:53 PM ET
    $GBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GBT alert in real time by email
    SC 13G/A 1 d301330dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    Global Blood Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    37890U 10 8

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 37890U 10 8

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Advisors LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      3,449,915

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      3,449,915

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,449,915

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      5.4%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA


    CUSIP No. 37890U 10 8

     

      1    

      NAMES OF REPORTING PERSONS

     

      Joseph Edelman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY

    OWNED BY 

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      3,449,915

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      3,449,915

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,449,915

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      5.4%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN


    CUSIP No. 37890U 10 8

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Life Sciences Master Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY

    OWNED BY 

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      3,449,915

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      3,449,915

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,449,915

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      5.4%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO


    Item 1(a).

    Name of Issuer:

    Global Blood Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    181 Oyster Point Boulevard

    South San Francisco, CA 94080

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $.001 par value (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    37890U 10 8

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 64,445,267 outstanding shares of Common Stock, as reported in the Issuer’s Form 10-Q filed on November 4, 2021.


    The Master Fund directly holds 3,449,915 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022

     

    PERCEPTIVE ADVISORS LLC

    By:

     

    /s/ Joseph Edelman

     

    Name: Joseph Edelman

     

    Title: Managing Member

     

    /s/ Joseph Edelman

    JOSEPH EDELMAN

     

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

    By:

     

    Perceptive Advisors LLC

    By:

     

    /s/ Joseph Edelman

     

    Name: Joseph Edelman

     

    Title: Managing Member

     

    Get the next $GBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GBT

    DatePrice TargetRatingAnalyst
    8/8/2022Outperform → Mkt Perform
    William Blair
    8/8/2022$40.00 → $72.00Hold → Buy
    Canaccord Genuity
    3/28/2022$138.00 → $71.00Outperform
    Wedbush
    2/28/2022$28.00 → $31.00Equal-Weight
    Morgan Stanley
    2/24/2022$92.00 → $86.00Outperform
    Oppenheimer
    12/21/2021$56.00 → $53.00Outperform
    SVB Leerink
    12/14/2021$54.00 → $56.00Outperform
    SVB Leerink
    12/7/2021Market Perform → Outperform
    William Blair
    More analyst ratings

    $GBT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

      Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA

      4/21/25 4:05:00 PM ET
      $DVAX
      $MRNA
      $SNY
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

      Issues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well

      2/19/25 9:00:00 AM ET
      $AVTE
      $DVAX
      $HZNP
      $MRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022

      SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell disease (SCD) treatment, research and education. The new legislation is sponsored by Congresswoman Barbara Lee of California, Congressman Danny Davis of Illinois, Senator Chris Van Hollen of Maryland and Senator Cory Booker of New Jersey. The bill would create a national network of SCD treatment centers in which healthcare providers and communit

      9/15/22 6:00:00 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Global Blood Therapeutics Inc.

      15-12G - Global Blood Therapeutics, Inc. (0001629137) (Filer)

      10/17/22 8:32:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Global Blood Therapeutics Inc.

      S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)

      10/5/22 4:41:14 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Global Blood Therapeutics Inc.

      S-8 POS - Global Blood Therapeutics, Inc. (0001629137) (Filer)

      10/5/22 4:40:32 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Patrick Deval L returned 9,037 shares to the company, closing all direct ownership in the company to cover withholding tax

      4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)

      10/6/22 4:20:58 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Thompson Alexis A. returned 3,308 shares to the company, closing all direct ownership in the company to satisfy tax liability

      4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)

      10/6/22 4:20:51 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Morrison Scott W returned 6,637 shares to the company, closing all direct ownership in the company (tax withholding)

      4 - Global Blood Therapeutics, Inc. (0001629137) (Issuer)

      10/6/22 4:20:56 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)

      SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)

      2/14/23 8:34:46 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)

      SC 13G/A - Global Blood Therapeutics, Inc. (0001629137) (Subject)

      2/9/23 10:59:20 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Global Blood Therapeutics Inc.

      SC 13G - Global Blood Therapeutics, Inc. (0001629137) (Subject)

      6/17/22 4:04:33 PM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    Financials

    Live finance-specific insights

    See more
    • Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

      Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmace

      8/8/22 6:45:00 AM ET
      $GBT
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022

      SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) --  Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close. Management will host a conference call on Monday, August 8, 2022, at 4:30 p.m. ET to discuss second quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the e

      7/29/22 8:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

      Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in patients 12 years of age and older. In addition, Phase 1 data of GBT021601 (GBT601), the company's next-generation sickle hemo

      6/10/22 3:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Global Blood Therapeutics downgraded by William Blair

      William Blair downgraded Global Blood Therapeutics from Outperform to Mkt Perform

      8/8/22 10:11:32 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Global Blood Therapeutics upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Global Blood Therapeutics from Hold to Buy and set a new price target of $72.00 from $40.00 previously

      8/8/22 7:23:49 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush resumed coverage on Global Blood Therapeutics with a new price target

      Wedbush resumed coverage of Global Blood Therapeutics with a rating of Outperform and set a new price target of $71.00 from $138.00 previously

      3/28/22 8:37:31 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBT
    Leadership Updates

    Live Leadership Updates

    See more
    • GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors

      SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of directors. Dr. Thompson, who brings decades of experience in clinical research, patient care, leadership and advocacy in hematology, will serve on the board’s research and development committee. “We’re thrilled to welcome Alexis to our board as we continue to pursue the transformation of care in sickle cell disease,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her deep expertise in blood

      3/18/21 7:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GBT Announces New Employment Inducement Grants

      SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2021, the compensation committee of GBT’s board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of dire

      1/7/21 8:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GBT Appoints Kim Smith-Whitley, M.D., to Lead Research and Development

      SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD) thought leader and advocate Kim Smith-Whitley, M.D., will join the company as executive vice president and head of research and development. “As we enter a period of expected sustained growth for years to come, aligning our research and development teams under a single leader will make GBT even more efficient and productive in bringing innovative medicines to patients. We are absolutely thrilled to add Kim, a committed and accomplished global leader in sickle cell disease, to our senior management

      12/7/20 8:00:00 AM ET
      $GBT
      Biotechnology: Pharmaceutical Preparations
      Health Care